Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes

NCT05533632 · Completed

Last updated 2026-05-28

This study is testing the safety of a weekly dose of semaglutide in adults with type 2 diabetes in Chile by tracking any side effects that occur.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 104 people

Who can join Ages 18+ · all sexes

Timeline Started 2022-04 · est. completion 2024-01

Where 3 sites · Chile

What this study is testing ClinicalTrials.gov NCT05533632 ↗

Description as written by the study sponsor.

This study is testing the safety and tolerability of subcutaneous semaglutide in participants with type 2 diabetes (T2D) in Chile. Participants will get a once-weekly subcutaneous injection of semaglutide in doses decided by the study doctor's criteria, according to participant's personal needs. The study will last for about 24 weeks. Participants will have 4 clinic visits and 2 phone calls. Participants will have 3 laboratory tests during the study (blood and urine samples).

Treatments tested

Semaglutide Drug

Participants will receive semaglutide s.c. injection once weekly in a dose escalation manner for 24 weeks.

Main thing measured	Number of Adverse Events (AEs)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05533632 ↗